Overview / Abstract: |
X-linked hypophosphatemia (XLH) is an inherited, lifelong disease of phosphate metabolism in which inactivating mutations of the PHEX gene causes a loss of phosphate wasting and leads to an increased concentration of fibroblast growth factor 23 (FGF23), which regulates the reabsorption of phosphate in the kidneys. Simply stated, XLH is known for increased secretion of FGF-23, which leads to hypophosphatemia and consequently osteomalacia, rickets, and skeletal deformities. The principle acquired form of FGF23-mediated hypophosphatemia is tumor-induced osteomalacia (TIO), a rare disease characterized by the development of phosphaturic mesenchymal tumors (PMTs) that are typically non-malignant and slow-growing. This accredited activity intends to close knowledge and practice gaps by addressing the link between both disorders. Devising treatment plans that incorporate the latest developments in the management of these disorders will also be addressed. |
Expiration |
Oct 21, 2021 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Webinar / Webcast / Video |
Credits / Hours |
1 |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Kathryn M. Dahir, MD |
Activity Specialities / Related Topics |
Endocrinology, Genetics, Pathology, Pediatrics, Perinatology, Primary Care, Radiology / Imagery / Nuclear Medicine, Surgery |
Sponsors / Supporters / Grant Providers |
Ultragenyx Pharmaceuticals |
Keywords / Search Terms |
EXCEL Continuing Education phosphate disorders, rickets, tumor-induced osteomalacia, hypophosphatemia, FGF-23. Free CE CME |